Journal article
AeroVax: study protocol for a randomised, double-blind, placebo-controlled, phase 2 trial to evaluate safety and immunogenicity of a next-generation COVID-19 vaccine delivered by inhaled aerosol to humans
Abstract
Background: Coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) continues to have a significant impact worldwide, in part due to a reduction in neutralising antibody protection provided by vaccines targeting monovalent spike antigens related to immune escape. Development of vaccines amenable for respiratory mucosal delivery that provide broad and durable immunity are needed. This study aims to …
Authors
Komorowski AS; Mbuagbaw L; Jeyanathan M; Afkhami S; Swinton M; D'Agostino MR; Howie K; Medina MFC; Gauvreau GM; Brister DL
Journal
ERJ Open Research, Vol. 11, No. 3, pp. 00758–02024
Publisher
European Respiratory Society (ERS)
DOI
10.1183/23120541.00758-2024
ISSN
2312-0541